Streetbeat News

Products Services

TCON

TRACON Pharmaceuticals announced that its ENVASARC Phase 2 pivotal trial is now fully enrolled, with final data expected in Q3 2024. This marks a significant milestone in the development of their treatment.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:12 pm

OGI

Organigram Holdings Inc. announced that its SHRED brand has surpassed $200 million in yearly retail sales, based on HiFyre data. This milestone highlights the brand's strong market presence and consumer acceptance.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:11 pm

AMRN

Amarin has been granted a new patent by the European Patent Office for VAZKEPA, extending its exclusivity by eight additional years until 2039. This development is significant for Amarin as it ensures prolonged market protection for VAZKEPA in Europe, potentially enhancing the company's revenue and market position in the cardiovascular treatment sector.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:10 pm

BHC

Bausch Health, Canada has announced that its product, (Pr)UCERIS(R) Aerosol Foam, designed for the treatment of mild to moderate distal ulcerative colitis in adults, has been listed for the first time on public drug plans. This development is aimed at addressing the unmet medical needs in this patient population.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:08 pm

IKT

Inhibikase Therapeutics has scheduled a pre-IND meeting with the FDA on April 5 to discuss IkT-001Pro, a potential treatment for Pulmonary Arterial Hypertension.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:07 pm

ICAD

iCAD, Inc. has announced a partnership with RAD-AID to enhance breast cancer detection in underserved regions through the use of artificial intelligence (AI). This collaboration aims to leverage iCAD's AI technology to improve early detection and treatment of breast cancer, potentially saving lives in areas with limited access to advanced medical technologies.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:06 pm

LIPO

Lipella Pharmaceuticals announced it will have an FDA Type C meeting regarding LP-10 for Hemorrhagic Cystitis on May 21. This step is crucial for advancing LP-10's regulatory pathway.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:02 pm

SXTP

60 Degrees Pharmaceuticals will sponsor a pilot study of Tafenoquine, the active molecule in its FDA-approved malaria prevention medication, Arakoda, for treating Babesiosis in dogs.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:01 pm

FXZ

SLX

X

United States Steel Corporation (NYSE:X) has signed a definitive agreement with CarbonFree to implement SkyCycle technology at its Gary Works Blast Furnaces, aiming to capture and mineralize 50,000 metric tons of CO2 annually. This initiative supports U.S. Steel's environmental goals, including a 20% reduction in greenhouse gas intensity by 2030 and net-zero emissions by 2050. The construction of the SkyCycle plant is expected to begin in summer 2024, with operations starting in 2026. The project, a first in North America, also offers investment opportunities through VanEck Steel ETF (NYSE:SLX) and First Trust Materials AlphaDEX Fund (NYSE:FXZ).

Portfolio Pulse from Nabaparna Bhattacharya

April 03, 2024 | 12:01 pm

TIPT

Tiptree Inc. has announced the rebranding of its asset management business to Tiptree Advisors, LLC. This strategic move is aimed at enhancing the company's brand identity and market presence.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 11:56 am